Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors

[1]  G. Stalla,et al.  Somatostatin receptors: From signaling to clinical practice , 2013, Frontiers in Neuroendocrinology.

[2]  M. Culler,et al.  The Novel Somatostatin Receptor 2/Dopamine Type 2 Receptor Chimeric Compound BIM-23A758 Decreases the Viability of Human GOT1 Midgut Carcinoid Cells , 2013, Neuroendocrinology.

[3]  E. Wolin,et al.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study , 2013, Cancer Chemotherapy and Pharmacology.

[4]  O. Keskin,et al.  A review of the use of somatostatin analogs in oncology , 2013, OncoTargets and therapy.

[5]  M. Caplin,et al.  Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. , 2013, Seminars in oncology.

[6]  C. Lombard-Bohas,et al.  Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors , 2013, European journal of gastroenterology & hepatology.

[7]  E. Krenning,et al.  Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. , 2012, Best practice & research. Clinical gastroenterology.

[8]  L. Kvols,et al.  Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. , 2012, Endocrine-related cancer.

[9]  L. Sidéris,et al.  Antitumor effects of somatostatin analogs in neuroendocrine tumors. , 2012, The oncologist.

[10]  E. Krenning,et al.  Lutetium-labelled peptides for therapy of neuroendocrine tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Stefano Severi,et al.  Yttrium-labelled peptides for therapy of NET , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  J. Bomanji,et al.  111In-DTPA0-octreotide (Octreoscan), 131I-MIBG and other agents for radionuclide therapy of NETs , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  P. Caron,et al.  Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. , 2012, The Journal of clinical endocrinology and metabolism.

[14]  G. Kaltsas,et al.  Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours , 2012, Endocrine-related cancer.

[15]  E. Krenning,et al.  Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy , 2012, Neuroendocrinology.

[16]  E. Baudin,et al.  ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.

[17]  R. Jensen,et al.  ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes , 2011, Neuroendocrinology.

[18]  J. Hainsworth,et al.  Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study , 2011, The Lancet.

[19]  L. Hofland,et al.  The role of somatostatin and dopamine D2 receptors in endocrine tumors. , 2011, Endocrine-related cancer.

[20]  R. Valkema,et al.  Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. , 2011, Endocrine-related cancer.

[21]  W. Ludlam,et al.  Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors , 2011, Advances in therapy.

[22]  M. Ferrari,et al.  Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  T. Gregersen,et al.  Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland , 2011, Neuroendocrinology.

[24]  E. D. de Vries,et al.  Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[25]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[26]  A. Vinik,et al.  Neuroendocrine Tumors: A Critical Appraisal of Management Strategies , 2010, Pancreas.

[27]  E. Van Cutsem,et al.  90Y-edotreotide for metastatic carcinoid refractory to octreotide. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Walecki,et al.  Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  E. Baudin,et al.  Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Michael Ljungberg,et al.  177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy , 2010, Cancer.

[31]  D. Goldstein,et al.  Antitumor effect of somatostatin analogs in neuroendocrine tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Eva Forssell-Aronsson,et al.  [177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney , 2010, World Journal of Surgery.

[33]  I. Modlin,et al.  Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours , 2009, Alimentary pharmacology & therapeutics.

[34]  R. Srirajaskanthan,et al.  Long‐term results of patients with malignant carcinoid syndrome receiving octreotide LAR , 2009, Alimentary pharmacology & therapeutics.

[35]  G. Wilding,et al.  High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. , 2009, Anticancer research.

[36]  E. Krenning,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs , 2009, Neuroendocrinology.

[37]  R. Srirajaskanthan,et al.  Expression of Somatostatin and Dopamine 2 Receptors in Neuroendocrine Tumours and the Potential Role for New Biotherapies , 2009, Neuroendocrinology.

[38]  M. Korbonits,et al.  Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. , 2008, Endocrine-related cancer.

[39]  G. Mamikunian,et al.  Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients , 2008, Pancreas.

[40]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Korbonits,et al.  The role of somatostatin analogues in the treatment of neuroendocrine tumours , 2008, Molecular and Cellular Endocrinology.

[42]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K. Hess,et al.  Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Barlier,et al.  The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. , 2006, European journal of endocrinology.

[45]  Raffaella Barone,et al.  Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. , 2006, Seminars in nuclear medicine.

[46]  E. Van Cutsem,et al.  Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide , 2004, Neuroendocrinology.

[47]  B. Skogseid,et al.  High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. , 2004, European journal of endocrinology.

[48]  S. Lamberts,et al.  Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. , 2003, Endocrine-related cancer.

[49]  S. Lamberts,et al.  The pathophysiological consequences of somatostatin receptor internalization and resistance. , 2003, Endocrine reviews.

[50]  M. Cremonesi,et al.  Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  G. Meno-Tetang,et al.  SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. , 2002, European journal of endocrinology.

[53]  R. Moncayo,et al.  111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial , 2002 .

[54]  C. Waldherr,et al.  The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  P. Ruszniewski,et al.  Treatment of carcinoid syndrome , 2000, Cancer.

[56]  R. Herrmann,et al.  Yttrium-90 DOTATOC: first clinical results , 1999, European Journal of Nuclear Medicine.

[57]  D. Hoyer,et al.  Molecular Pharmacology of Somatostatin‐receptor Subtypes , 1994, Annals of the New York Academy of Sciences.

[58]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[59]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.

[60]  L. Krulich,et al.  Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. , 1968, Endocrinology.

[61]  C. Schade-Brittinger,et al.  Placebo-Controlled , Double-Blind , Prospective , Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors : A Report From the PROMID Study Group , 2009 .

[62]  M. Essen,et al.  et al Treatment with the radiolabeled somatostatinanalog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology : , 2008 .

[63]  Marion de Jong,et al.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  L. Kvols,et al.  Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  S. Lamberts,et al.  Drug therapy : octreotide , 1996 .